JosephDKhouryMD

PubMed

• 1 citations
  Can molecular patterns help to classify overlapping entities in myeloid neoplasms?
  Gregor Hoermann, Joseph D Khoury
  Histopathology. 2025-01-01
• Correspondence response to: can patient ancestry influence molecular classifications in myeloid neoplasms?
  Gregor Hoermann, Yuri Fedoriw, Joseph D Khoury
  Histopathology. 2024-12-20
• 1 citations
  Integrative immunophenotypic and genetic characterization of acute myeloid leukemia with CBFB rearrangement.
  Fnu Sameeta, Sa A Wang, Zhenya Tang, Joseph D Khoury, Hong Fang
  American Journal of Clinical Pathology. 2024-11-04

Journal Articles

• CD123 Expression Patterns and Selective Targeting with a CD123-Specific Antibody-Drug Conjugate (IMGN632) in Acute Lymphoblastic Leukemia  
  L Jeffrey Medeiros, Hagop M Kantarjian, Jeffrey L Jorgensen, Marina Konopleva, Elias J Jabbour, Joseph D Khoury, Sa A Wang, Sergej N Konoplev, Haematologica
• Focal Rosai–Dorfman Disease Coexisting with Lymphoma in the Same Anatomic Site: A Localized Histiocytic Proliferation Associated with MAPK/ERK Pathway Activation  
  Shaoying Li, L Jeffrey Medeiros, Joseph D Khoury, Nature
• Clinicopathologic and Molecular Features in Hairy Cell Leukemia-Variant: Single Institutional Experience  
  Tariq Muzzafar, L Jeffrey Medeiros, Xinyan Lu, Joseph D Khoury, Nature

Abstracts/Posters

• Efficacy of Targeted Therapy in Novel Pre-Clinical in Vitro and In Vivo Models of Richter Transformation-Diffuse Large B-Cell Lymphoma (RT-DLBCL)
  Joseph D. Khoury, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR)
  Joseph D. Khoury, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• p53 Mediated Bone Marrow Mesenchymal Stem Cell Expansion Supports Acute Myeloid Leukemia Development
  Joseph D. Khoury, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement
  Joseph D. Khoury, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• AXL/Mertk Inhibitor ONO-7475 Potently Synergizes with BCL2 Inhibitor ABT-199, Overcomes ABT-199 Resistance Mechanisms, and Kills FLT3 ITD AML Cells
  Joseph D. Khoury, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)
  Joseph D. Khoury, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in O...
  Joseph D. Khoury, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics ...
  Joseph D. Khoury, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis
  Joseph D. Khoury, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia Is a Strong P...
  Joseph D. Khoury, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) w...
  Joseph D. Khoury, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Loss of EZH2 Protein Expression in Myelodysplastic Syndrome Correlates with EZH2 Mutation and Portends a Worse Outcome
  Joseph D. Khoury, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Pre-Clinical Efficacy of Co-Treatment with KDM1A (LSD1) Inhibitor and Ruxolitinib or BET Inhibitor Against Post-MPN-sAML Blast Progenitor Cells
  Joseph D. Khoury, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
  Joseph D. Khoury, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Myelodysplastic Syndromes: Laboratory Workup in the Context of New Concepts and Classification Criteria
  Joseph Khoury, MD, Current Hematologic Malignancy Reports, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Novel BET Protein Degrader-Based Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β-Catenin-TCF7L2- MYC Axis 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromoso... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Mechanisms Underlying Superior Efficacy of Co-Targeting BET Proteins and Anti-Apoptotic BCL2 or MCL1 Protein Against AML Blast Progenitor Cells 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all